Admilparant
From Wikipedia, the free encyclopedia
Chemical compound
This article is an orphan, as no other articles introduce links to this page from related articles ; try the Find link tool for suggestions. (November 2024)
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | BMS-986278 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H31N5O5 |
| Molar mass | 445.520 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Admilparant is an investigational new drug being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist.[1] [2]
As of 2024, admilparant is in Phase III clinical trials for both IPF and PPF.[2] [3]
References
[edit ]- ^ "Admilparant (BMS-986278): Idiopathic Pulmonary Fibrosis Likelihood of Approval". Pharmaceutical Technology. 25 December 2023. Retrieved 2024年11月23日.
- ^ a b Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, et al. (October 2024). "Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial". American Journal of Respiratory and Critical Care Medicine. doi:10.1164/rccm.202405-0977OC. PMID 39393084.
- ^ Splete H (16 September 2024). "Admilparant Affects Biomarkers in Pulmonary Fibrosis". Medscape. Retrieved 2024年11月23日.
Stub icon
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.